Cell-based vaccination against melanoma - Background, preliminary results, and perspective

Journal of Molecular Medicine

Volumn 77, Issue 8, 1999, Pages 593-608

  Sun, Yuansheng ^b   Paschen, Annette ^b   Schadendorf, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

Cytokine gene transfer; Dendritic cells; Immune response; Tumor cell vaccine; Tumor specific T cells

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; GENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PHASE 3 CLINICAL TRIAL; REVIEW; SEQUENCE ANALYSIS;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE I; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; HUMANS; MELANOMA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0343240340     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001099900039     Document Type: Review

References (150)

1. 1. Johnson TM, Smith JW, Nelson BR, Chang A (1995) Current therapy for cutaneous melanoma. J Am Acad Dermatol 32:689-707
2. 2. Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schoid DJ (1989) Complete responses and long-term survivals after systemic chemotherapy for patients with advanced melanoma. Cancer 63:224-227
3. 3. Balch CM, Houshton A, Peters L (1989) Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 1499-1542
4. 4. Oettgen HF, Old LJ (1991) The history of cancer immunotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) The biologic therapy of cancer: principles and practice. Lippincott, Philadelphia, pp 87-119
5. 5. Clark WH Jr, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-727
6. 6. Clark WH Jr, Elder DE, Guerry DP, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904
7. 7. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310
8. 8. Mackensen A, Carcelain G, Viel S, Raynal MC, Michalaki H, Triebel F, Bosq J, Hercend T (1994) Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 93:1397-1402
9. 9. Kirkwood JM, Ernstoff MS (1990) Role of interferons in the therapy of melanoma. J Invest Dermatol 95 [Suppl]: 180S-184S
10. 10. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-485
11. 11. Ollila DW, Kelley MC, Gammon G, Morton-DL (1998) Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 14:328-336
12. 12. Kirkwood JM (1991) Studies of interferons in the therapy of melanoma. Semin Oncol 18:83-90
13. 13. Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7:7-20
14. 14. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166
15. 15. Rosenberg SA (1996) Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 88:1635-1644
16. 16. Morton DL, Barth A (1996) Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244
17. 17. Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D (1996) Active specific immunization in the treatment of patients with melanoma. Semin Oncol 23:773-781
18. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470-476
19. 19. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327
20. 20. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8:1858-1867
21. 21. Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ (1997) Autologous, hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359-2370
22. 22. Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC Jr (1998) Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 25:646-653
23. 23. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17
24. 24. Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, Parmiani G, Berd D (1997) Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest 99:710-717
25. 25. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482
26. 26. Morton DL, Barth A (1996) Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244
27. 27. Chan AD, Morton DL (1998) Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 25:611-622
28. 28. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S (1988) Active specific immunotherapy for melanoma. Phase 1 trial of allogeneic melanoma lysates and a novel adjuvant. Cancer Res 48:5883-5893
29. 29. Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, Goedegebuure P, Huang XQ, Hofman F, Groshen S (1993) Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 690:153-166
30. 30. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L (1990) Active specific immunotherapy for melanoma. J Clin Oncol 8:856-869
31. 31. Mitchell MS, Harel W, Groshen S (1992) Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10:1158-1164
32. 32. Elliott GT, McLeod RA, Perez J, Von Eschen KB (1993) Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 9:264-272
33. 33. Mitchell MS (1998) Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25:623-635
34. 34. Wallack MK, McNally KR, Leftheriotis E, Seigler H, Balch C, Wanebo H, Bartolucci AA, Bash JA (1986) A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer 57:649-655
35. 35. Wallack MK, Scoggin SD, Sivanandham M (1992) Active specific immunotherapy with vaccinia melanoma oncolysate. Mt Sinai J Med 59:227-233
36. 36. Wallack MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Rosen L, Bartolucci AA (1997) Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multiinstitutional trial. Ann Surg 226:198-206
37. 37. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L (1998) Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187:69-77
38. 38. Bystryn JC, Jacobsen S, Harris M, Roses D, Speyer J, Levin M (1986) Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Response Mod 5:211-224
39. 39. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R (1992) Relationship between immune response to melanoma vaccine and clinical outcome in stage II malignant melanoma. Cancer 69:1157-1164
40. 40. Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris MN, Bystryn JC (1995) Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495-502
41. 41. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M (1986) Tumor inhibition by interleukin-2 at the tumor/host interface. Biochim Biophys Acta 865:307-327
42. 42. Forni G, Musso T, Jemma C, Boraschi D, Tagliabue A, Giovarelli M (1989) Lymphokine-activated tumor inhibition in mice: ability of a nonapeptide of the human IL-1 beta to recruit anti-tumor reactivity in recipient mice. J Immunol 142:712-718
43. 43. Pizza G, Severini G, Menniti D, De-Vinci C, Corrado F (1984) Tumor regression after intralesional injection of interleukin 2 in bladder cancer. Preliminary report. Int J Cancer 34:359-367
44. 44. Giovarelli M, Cofano F, Vecchi A, Forni M, Landolfo S, Forni G (1986) Interferon-activated tumor inhibition in vivo. Small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity. Int J Cancer 37:141-148
45. 45. Canevari S, Pupa SM, Menard S (1996) 1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol 7:227-232
46. 46. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676-1680
47. 47. Zinkernagel RM, Callahan GN, Althage A, Cooper S, Streilein JW, Klein J (1978) The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T cell help. J Exp Med 147:897-911
48. 48. von Boehmer H, Haas W (1979) Distinct Ir genes for helper and killer cells in the cytotoxic response to H-Y antigen. J Exp Med 150:1134-1142
49. 49. Keene J, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155:768-782
50. 50. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480
51. 51. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483
52. 52. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503-512
53. 53. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T, Skata T (1989) Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86:9456-9460
54. 54. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Livitsky HI, JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
55. 55. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
56. 56. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990) Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long-lasting anti-tumor immunity. Cancer Res 50:7820-7825
57. 57. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415
58. 58. Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48-51
59. 59. Vieweg J, Gilboa E (1995) Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Invest 13:193-201
60. 60. Gilboa E (1996) Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 23:101-107
61. 61. Gilboa E, Lyerly HK, Vieweg J, Saito S (1994) Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol 5:409-417
62. 62. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L (1993) Anti-metastatic vaccination of tumor-bearing mice with two types of gamma-interferon gene inserted tumor cells. J Immunol 150:1458-1463
63. 63. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, Eisenbach L (1993) Antimetastatic vaccination of tumor bearing mice wilh IL-2 gene inserted tumor cells. Int J Cancer 53:471-477
64. 64. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L (1992) Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679-3686
65. 65. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumors in mice treated with interleukin 2-gene-modified tumor cells. J Exp Med 177:1127-1134
66. 66. Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WD, Fair WR, Gilboa E (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 54:3516-3520
67. 67. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines. Cancer Res 54:1760-1765
68. 68. Dranoff G, Jaffee F, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan R (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
69. 69. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B (1994) Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood 83:1289-1298
70. 70. Cao X, Chen C, Zhang W, Tao Q, Yu Y, Yc T (1996) Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 3:421-426
71. 71. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamantstein T, Blankenstein T (1993) Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53:714-716
72. + T cells by B7-transfected melanoma cells. Science 259:368-370
73. 73. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
74. 74. Cayeux S, Beck C, Dörken B, Blankenstein T (1996) Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 7:525-529
75. 75. Cayeux S, Beck C, Aicher A, Dörken B, Blankenstein T (1995) Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 25:2325-2331
76. 76. Salvadori S, Gansbacher B, Wernick I, Tirelli S, Zier K (1995) B7.1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 6:1299-1306
77. 77. Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL (1995) B7.1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55:4980-4987
78. 78. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner F, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML (1995) Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine: assessment of critical cellular and molecular parameters. J Immunol 154:3406-3419
79. 79. Schneeberger A, Koszik F, Stingl G (1995) Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol 105:110S-116S
80. 80. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamantstein T, Blankenstein T (1993) Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53:714-716
81. 81. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L, Forni G (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54:6022-6026
82. 82. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B (1992) Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52:6229-6236
83. 83. Jaffee EM, Dranoff G, Cohen LK, Hauda KM, Clift S, Marshall FF, Mulligan RC, Pardoll DM (1993) High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 53:2221-2226
84. 84. Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Ettinghausen SE, Parkinson DN, White DE (1993) The development of gene therapy for the treatment of cancer. Ann Surg 218:455-464
85. 85. Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 88:21-39
86. 86. Lotze MT, Rubin JT, Carty S, Edington H, Ferson P, Landreneau R, Pippin B, Posner M, Rosenfelder D, Watson C (1994) Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5:41-55
87. 87. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 2:1263-1274
88. 88. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327-1335
89. 89. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77:1492-1494
90. 90. Schadendorf D, Czarnetzki BM, Wittig B (1995) Clinical protocol - interleukin-7-, interleukin-12-, and GM-CSF gene transfer in patients with metastatic melanoma. J Mol Med 73:473-477
91. 91. Schadendorf D, Henz BM, Wittig B (1996) Interleukin 7 trials for melanoma treatment. Mol Med Today 2:143-144
92. 92. Sun Y, Jurgovsky K, Möller P, Alijagic S, Dorbic T, Georgieva J, Wittig B, Schadendorf D (1998). Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5:481-490
93. 93. Möller P, Sun Y, Dorbic T, Möller H, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D (1998). Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 77:1907-1916
94. 94. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95:13141-13146
95. 95. Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF (1997) A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80:401-412
96. 96. Arienti F, Sule-Suso J, Belli F, Macheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo MP, Parmiani G (1996) Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 7:1955-1963
97. 97. Belli F, Arienti F, Sule-Suso J, Clemente C, Mascheroni L, Cattelan A, Sanantonio C, Gallino GF, Melani C, Rao S, Colombo MP, Maio M, Cascinelli N, Parmiani G (1997) Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197-203
98. 98. Veelken H, Mackensen A, Lahn M, Köhler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Schultze-Seemann W, Farthmann EH, Mertelsmann R, Lindemann A (1997) A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 70:269-277
99. 99. Mackensen A, Veelken H, Lahn M, Wittnebel S, Becker D, Köhler G, Kulmburg P, Brennscheidt U, Rosenthal F, Franke B, Mertelsmann R, and Lindemann A (1997) Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J Mol Med 75:290-296
100. 100. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
101. 101. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J (1992) GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261
102. 102. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93
103. 103. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-alpha. J Exp Med 179:1109-1111
104. 104. Grabbe S, Beissert S, Schwarz T, Granstein RD (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for immunotherapy? Immunol Today 16:117-121
105. 105. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo-AB, Clarke-MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87-97
106. 106. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322
107. 107. Mayordomo JI, Zorina T, Storkus WJ, Celuzzi CM, Falo LD, Kast WM, Ildstad ST, DeLeo AB, Lotze MT (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1:1297-1302
108. 108. Peters JH, Gieseler R, Thiele B, Steinbach F (1996) Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol Today 17:273-278
109. 109. Boon T, Gajewski TF, Coulic PG (1995) From defined human tumor antigens to effective immunization. Immunol Today 16:334-337
110. 110. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT (1996) New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11-24
111. 111. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182
112. 112. Nair SK, Boczkowski D, Snyder D, Gilboa E (1997) Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27:589-597
113. 113. Alijagic S, Möller P, Jurgovsky K, Czarnetzki BM, Schadendorf D (1995) Transaction of dendritic cells generated from peripheral blood with human tyrosinase induced specific T-cell activation. Eur J Immunol 25:3100-3107
114. 114. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58
115. 115. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 92:8078-8082
116. 116. Nestle FO, Alijagic S, Gilliet M, Sun Y, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332
117. 117. Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316
118. 118. Jonuleit H, Kühn U, Müller C, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk A (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135-3142
119. 119. Bueler H, Mulligan RC (1996) Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte colony-stimulating factor and B7-1. Mol Med 2:545-555
120. 120. McArthur JG, Mulligan RC (1998) Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 21:41-47
121. 121. Boczkowski D, Nair SK, Synder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
122. 122. Wortzel RD, Philipps C, Schreiber H (1983) Multiple tumor-specific antigens expressed on a single tumor cell. Nature 304:165-167
123. 123. Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178-186
124. 124. Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311:750-752
125. 125. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M (1985) Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301-305
126. 126. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR, Mule JJ, Yewdell JW, Rosenberg SA (1991) Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor response. J Immunol 147:1453-1459
127. 127. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT (1996) New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11-24
128. 128. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J-C, Tschopp L (1996) Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366
129. 129. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells - a mechanism of immune evasion? Nat Med 2:1361-1366
130. 130. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas ligand. J Exp Med 184:1075-1082
131. 131. Seino KI, Kayagaki N, Okumura K, Yagita H (1997) Antitumor effect of locally produced CD95 ligand. Nat Med 3:165-170
132. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161:1220-1230
133. 133. Miescher S, Whiteside TL, Carrel S, von Fliedner V (1986) Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899-1907
134. 134. Luscher U, Filgueira L, Juretic A, Zuber M, Luscher NJ, Heberer M, Spagnoli GC (1994) The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 57:612-619
135. 135. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798
136. 136. Salvadori S, Gansbacher B, Pizzimenti AM, Zier KS (1994) Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J Immunol 153:5176-5182
137. 137. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765-772
138. 138. Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, Peereboom D, Olencki T, Budd GT, McLain D, Elson P, Novick A, Finke JH (1998) Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4:2337-2347
139. 139. Reichert TH, Day R, Wagner EM, Whiteside TL (1998) Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58:5344-5347
140. 140. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1998) Mechanisms responsible for signaling and functional defects. J Immunother 21:295-306
141. 141. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383-1390
142. 142. Dummer R, Yue FY, Pavlovic J, Geertsen R, Dohring C, Moelling K, Burg G (1998) Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Br J Cancer 77:1413-1419
143. 143. Schmid P, Itin P, Rufli T (1995) In situ analysis of transforming growth factor-betas (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16:1499-1503
144. 144. Chu JW, Sharom FJ (1993) Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunology 79:10-17
145. 145. Ling W, Rayman P, Uzzo R, Clark P, Kim HJ, Tubbs R, Novick A, Bukowski R, Hamilton T, Finke J (1998) Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IκBα. Blood 92:1334-1341
146. 146. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD (1995) IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 154:1280-1286
147. + T cells resulting in a failure to lyse tumor cells. Blood 93:1634-1642
148. 148. Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R (1998) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161:2099-2105
149. 149. Ma D, Niederkorn JY (1995) Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86:263-269
150. 150. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345-350